Reframing Preclinical Evaluation: Decoding FDA's 2026 Guidance on New Approach Methodologies

Medicine Bulletin 2026 Open access

Read full text

Authors: Zhongjun Wan, Xisheng Li, H Li, Liangbin Zhou

DOI: 10.1002/mdb2.70039

Cited by: 1

References: 5

Abstract

The authors declare no conflicts of interest. Data sharing is not applicable to this article as no new data were created or analyzed.

Immunotoxicology and immune responses Animal testing and alternatives Statistical Methods in Clinical Trials

References 5